ABVC Biopharma Files 8-K on Director Changes
Ticker: ABVC · Form: 8-K · Filed: Jul 23, 2024 · CIK: 1173313
| Field | Detail |
|---|---|
| Company | Abvc Biopharma, Inc. (ABVC) |
| Form Type | 8-K |
| Filed Date | Jul 23, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001, $296,000, $24M, $19M, $23.7M |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-compensation, board-of-directors
TL;DR
ABVC Bio just filed an 8-K - board shakeup and exec comp changes incoming.
AI Summary
On July 23, 2024, ABVC Biopharma, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing indicates the election of new directors and potential adjustments to compensatory arrangements for certain officers, though specific names and dollar amounts related to compensation were not detailed in the provided text.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy, governance, or financial outlook, impacting investor confidence.
Risk Assessment
Risk Level: medium — The filing indicates changes in corporate governance and executive compensation, which can introduce uncertainty.
Key Players & Entities
- ABVC BIOPHARMA, INC. (company) — Registrant
- July 23, 2024 (date) — Date of Report
- Nevada (jurisdiction) — State of Incorporation
FAQ
What specific changes were made to the board of directors?
The filing indicates the election of directors and departure of certain officers, but the specific names of individuals elected or departing were not detailed in the provided text.
Are there any details on the new compensatory arrangements for officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item, but specific details, dollar amounts, or terms of these arrangements were not provided in the excerpt.
What is the primary reason for this 8-K filing?
The 8-K filing is primarily to report on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements of certain officers, as well as other events.
When was ABVC Biopharma incorporated?
ABVC Biopharma, Inc. was incorporated in Nevada.
What is the company's Standard Industrial Classification (SIC) code?
The company's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 571 words · 2 min read · ~2 pages · Grade level 12.3 · Accepted 2024-07-23 17:00:34
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share ABVC The Nasdaq Stock Mar
- $296,000 — lease titled, " ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License
- $24M — t of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl
- $19M — ntial aggregate license fee is actually $19M. Additionally, the Press Release stated
- $23.7M — xpects to receive up to an aggregate of $23.7M in cash from all three licensees (AiBtl
- $18.7M — possible cash payment is expected to be $18.7M. 1 SIGNATURE Pursuant to the requi
Filing Documents
- ea020990501-8k_abvcbio.htm (8-K) — 24KB
- 0001213900-24-063627.txt ( ) — 192KB
- abvc-20240723.xsd (EX-101.SCH) — 3KB
- abvc-20240723_lab.xml (EX-101.LAB) — 33KB
- abvc-20240723_pre.xml (EX-101.PRE) — 22KB
- ea020990501-8k_abvcbio_htm.xml (XML) — 3KB
02 Departure of Directors or Principal Officers;
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers ABVC BioPharma, Inc. (the "Company") and its CFO, Leeds Chow are currently negotiating the terms of his employment agreement; due to disagreements regarding salaries due and payable, Mr. Chow has informed the Company that he is suspending his work as CFO. The disagreement relates solely to salary owed and payable to Mr. Chow and is not the result of any disagreements with the Company on any matter related to the Company's disclosures in its public filings. The Company's CEO, Uttam Patil, will assume the duties of interim Chief Financial Officer until the parties settle the disagreement and Leeds resumes his position as CFO. Item 8.01 Other Events The Company also seeks to correct two typos contained in the press release titled, " ABVC BioPharma Receives $296,000 Cash Out of Potential Aggregate License Fee of $24M Cash and Stock From Its Licensees AiBtl, ForSeeCon and OncoX in Global Licensing Deals," which was disseminated on July 2, 2024 (the "Press Release"). The potential aggregate license fee is actually $19M. Additionally, the Press Release stated that the Company expects to receive up to an aggregate of $23.7M in cash from all three licensees (AiBtl, ForSeeCon, and OncoX), but the total possible cash payment is expected to be $18.7M. 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ABVC BioPharma, Inc. July 23, 2024 By: /s/ Uttam Patil Uttam Patil Chief Executive Officer 2